Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Immunotherapy

Novel modified T cells enable more-specific tumour targeting

Nature Reviews Clinical Oncology volume 13, pages 716–717 (2016)Cite this article

Subjects

This article has been updated

The development of chimeric antigen receptor (CAR) T cells has enabled the highly specific targeting of selected tumour antigens, and has improved the outcomes of patients with certain types of cancer. However, various limitations in the clinical effectiveness of CAR T cells remain, mostly owing to the need for an endogenous T-cell response that can result in toxic adverse effects and an inability to overcome immunosuppressive signals in the tumour microenvironment.

In order to address these limitations of second-generation and third-generation CAR T cells, researchers are developing novel T-cell-based therapeutics capable of not only recognition, but also targeted delivery of specific therapeutics. Two newly published studies in Cell reveal promising approaches that might lead to improvements in patient outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 20 October 2016

    Two quotes in this article were originally incorrectly ascribed to Wendell Lim, and not Hans-Guido Wendel. This error has been corrected in the online and PDF versions of this article.

References

  1. Boice, M. et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell http://dx.doi.org/10.1016/j.cell.2016.08.032 (2016)

  2. Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell http://dx.doi.org/10.1016/j.cell.2016.09.011 (2016)

Download references

Authors
  1. Peter Sidaway
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. Novel modified T cells enable more-specific tumour targeting. Nat Rev Clin Oncol 13, 716–717 (2016). https://doi.org/10.1038/nrclinonc.2016.169

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.169

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research